Decade of HAART: Slide Sets

Editor's Note: The International Association of Physicians in AIDS Care (IAPAC) convened "A Decade of HAART: Historical Perspectives and Future Directions" in San Francisco, California, September 25-26, 2006. A number of leading HIV experts reviewed critical issues in the field since the advent of what is known as highly active antiretroviral therapy, or HAART. Click on the links below to view PDF versions of selected slide sets from this meeting.

A Decade of HAART: Historical Perspectives, Successes, Challenges, and Future Considerations
Anthony Fauci, MD, Director of NIAID, evaluated the scientific and medical advances over the last quarter century, as well as critical challenges that lie ahead in the battle against AIDS.

Changes in HIV Drug Resistance in the HAART Era
Deenan Pillay, MD, PhD, of Royal Free and University College in London, discussed the prevalence of ARV drug resistance mutations and reviewed the clinical implications of baseline resistance in HIV-infected patients.

Delivered From Death's Door: 10 Years of Pediatric AIDS Advances
Paul Palumbo, MD, of the New Jersey Medical School, explained advances and future challenges in the management of HIV-infected children.

Future Trends in HIV Research and Clinical Management
Brian Gazzard, MD, of Chelsea and Westminster Hospital in London, provided his expert assessment of where the field is heading in terms of HIV management trends, prevention strategies, and investigational agents.

Economic History of HIV Care
Samuel Bozzette, MD, PhD, of University of California, San Diego, explained a number of critical points in regard to the evolution of HIV-related healthcare expenditures in the United States.

To Hell and Back: 25 Years With HIV
Martin Delaney, founder of Project Inform, provided the perspective of an activist who has been on the front lines of fighting AIDS since the beginning of the pandemic.

Predicting Morbidity and Mortality in South Africa
Sally Blower, PhD, of the University of California, Los Angeles, reviews epidemiologic data from urban and rural settings in South Africa, and examines how drug allocation strategies might affect HIV-related morbidity and mortality in this geographic region.